The effect of sodium-glucose cotransporter-2 inhibitors (SGLT-2is) on the renin-angiotensin-aldosterone system (RAAS) in type 2 diabetes mellitus (T2DM) remains controversial [12], as they may either activate or inhibit RAAS, potentially impacting the accuracy of ARR in diagnosing primary aldosteronism (PA) [7]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.